Ovid Therapeutics
OVID
62 hedge funds and large institutions have $110M invested in Ovid Therapeutics in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 22 increasing their positions, 17 reducing their positions, and 12 closing their positions.
29% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 17
1% more capital invested
Capital invested by funds: $109M → $110M (+$1.12M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.03% less ownership
Funds ownership: 49.96% → 49.92% (-0.03%)
7% less funds holding
Funds holding: 67 → 62 (-5)
42% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
CHI Advisors
New York
|
+$1.42M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$1.13M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$772K |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$692K |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$667K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$2.46M |
| 2 |
GC
Globeflex Capital
San Diego,
California
|
-$289K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$252K |
| 4 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$176K |
| 5 |
B
Bailard
Foster City,
California
|
-$154K |
OVID Hedge Fund Activity: Q1 2022 in Review
62 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q1 2022, worth a combined $110M — up 1% from $109M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of OVID and 7 opened new positions — a net loss of 5 holders — while 17 trimmed existing stakes and 22 added.
The largest buyer was CHI Advisors, adding an estimated $1.42M. The largest seller was Platinum Investment Management, exiting entirely with an estimated $2.46M sold.
- 62 institutional investors held Ovid Therapeutics (OVID) as of Q1 2022, down from 67 in Q4 2021.
- Funds reported $110M of Ovid Therapeutics stock for Q1 2022, up 1% quarter-over-quarter.
- 7 funds opened new Ovid Therapeutics positions in Q1 2022 and 12 closed out, a net change of -5 holders.
- The largest Ovid Therapeutics buyer in Q1 2022 was CHI Advisors, an estimated $1.42M added.
- The largest Ovid Therapeutics seller in Q1 2022 was Platinum Investment Management, an estimated $2.46M sold.
Based on aggregated 13F filings for Q1 2022.